“Can a purpose-built GenAI platform — trained on clinical and financial data at the health-system level — meaningfully reduce administrative costs and improve revenue integrity across the entire healthcare revenue cycle?”
Founded in 2019, AKASA began as an AI automation company for healthcare revenue cycle management (RCM), initially applying machine learning to tasks like claim status and prior authorization. As generative AI matured, AKASA pivoted to building custom large language models (LLMs) trained on each health system's clinical data, repositioning itself as the leading GenAI platform for the mid-revenue cycle — spanning coding, CDI, and clinical denials. The Cleveland Clinic partnership in 2025 cemented AKASA's position as a serious enterprise GenAI player in healthcare finance, with no embedded finance products of its own.
AKASA was founded by Varun Ganapathi and Co-founders unnamed in evidence and is founded in 2019, headquartered in South San Francisco, California, USA.
AKASA has raised $205M in total (latest round: Series unknown, 2025 (Cleveland Clinic collaboration announced April 2025)).
Get a read on where your own stack stands against AKASA and the rest of its category — what they built versus bought, which providers they use, and where the gaps in your own strategy and competitive set actually are.